CliffBio
small molecule

MYHIBBIN

MYCOPHENOLATE MOFETIL

Loss of exclusivityAugust 2039latest FDA-listed patent expiry
CompanyAzurity Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameMYHIBBIN
Active ingredientMYCOPHENOLATE MOFETIL
Strength200MG/ML
Dosage formSUSPENSION
RouteORAL
ModalitySmall molecule
FDA approvalMay 2024
Marketing statusRX

Listed patents

PatentExpiresType
12194143August 2039product
12097285August 2039product
12226526August 2039product
11931455August 2039product
12097284August 2039product

More from Azurity Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

MYHIBBIN patent cliff — loss of exclusivity August 2039 | CliffBio